Neurolief is dedicated to bringing relief to patients with chronic neurological and neuropsychiatric disorders. The company has created a digital therapeutics platform of clinically proven neuromodulation-based solutions that can be delivered to patients at home or in the community. Neurolief's Relivion is a noninvasive, multichannel brain neuromodulation system for treating neurological and neuropsychiatric disorders. It offers precise, personalized care by delivering stimulation to six branches of the occipital and trigeminal nerves via three adaptive output channels. This creates a cumulative effect by releasing neurotransmitters in the brainstem to modulate the brain networks associated with pain and mood control. The Relivion device is placed comfortably on the patient's head, where it stimulates the nerves. The connected e-Relief mobile app displays the treatment status and transmits information between patients and the cloud. In July 2019, Neurolief received the CE mark for Relivion, allowing the company to market, sell, and distribute the device as an over-the-counter therapy within the European Union and countries that participate with agreements on mutual recognition of conformity assessment.